FDA Panel Ends Peptide Review Backing Six of Seven, with Emideltide Rejected in a 6 to 7 Vote

FDA’s compounding panel backed six of seven peptides and rejected emideltide 6-7. What the votes mean for patients buying BPC-157 and semax.

Have A Referral?